Company

TSE 4974

タカラバイオ

4974 · TSE · Chemicals

Financials Consolidated

Revenue¥45.0bn+3.5% year on yearConsolidated · FY3/25

Ordinary profit¥2.59bn−23.9% year on yearConsolidated · FY3/25

Net profit¥1.04bn−29.7% year on yearConsolidated · FY3/25

Dividend per share¥17.00FY3/25

Revenue

¥46.1bnFY3/21

¥67.7bnFY3/22

¥78.1bnFY3/23

¥43.5bnFY3/24

¥45.0bnFY3/25

Ordinary profit

¥14.2bnFY3/21

¥28.5bnFY3/22

¥20.7bnFY3/23

¥3.41bnFY3/24

¥2.59bnFY3/25

Net profit (attributable)

¥9.55bnFY3/21

¥19.8bnFY3/22

¥16.0bnFY3/23

¥1.48bnFY3/24

¥1.04bnFY3/25

Op. cash flow

¥13.9bnFY3/21

¥6.99bnFY3/22

¥36.9bnFY3/23

¥1.71bnFY3/24

¥5.84bnFY3/25

Employees, whole group1,779 peopleFY3/25

Employees, parent company (non-consolidated)762 peopleFY3/25

Average salary¥6.80mFY3/25

Average salary is for the parent company's own employees (non-consolidated), as Japanese annual reports disclose it.

Five-year history

Five-year history
Fiscal year	Revenue	Ordinary profit	Net profit (attributable)	EPS	Dividend	Total assets	Net assets	Op. cash flow
FY3/25	¥45.0bn+3.5% year on year	¥2.59bn	¥1.04bn	¥8.65	¥17.00	¥125.3bn	¥115.8bn	¥5.84bn
FY3/24	¥43.5bn−44.3% year on year	¥3.41bn	¥1.48bn	¥12.30	¥17.00	¥121.3bn	¥111.8bn	¥1.71bn
FY3/23	¥78.1bn+15.4% year on year	¥20.68bn	¥16.01bn	¥132.97	¥42.00	¥129.2bn	¥112.5bn	¥36.90bn
FY3/22	¥67.7bn+46.9% year on year	¥28.46bn	¥19.85bn	¥164.84	¥33.00	¥115.7bn	¥96.1bn	¥6.99bn
FY3/21	¥46.1bn	¥14.16bn	¥9.55bn	¥79.29	¥16.00	¥89.8bn	¥74.3bn	¥13.94bn

Per-share figures are as each report states them: a share split is restated only for the year before it, and dividends are as paid.

Figures from annual report S100VZNP · Japan GAAP. Each figure's years come from one report's five-year summary.